Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hotta, K.
Kiura, K.
Takigawa, N.
Tabata, M.
Fujiwara, Y.
Tanimoto, M.
机构：
[1] Okayama Univ, Grad Sch Med, Dept Hematol Oncol & Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ, Tsuyama Cent Hosp, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7624
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [22] Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer
    Zhao, Shen
    Zhang, Zhonghan
    Zhang, Yaxiong
    Hong, Shaodong
    Zhou, Ting
    Yang, Yunpeng
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (11) : 2854 - 2866
  • [23] Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Friedlander, Michael
    Marschner, Ian
    Simes, John
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Effect of the quality of the methodology on the relationship between progression-free survival (PFS) and overall survival (OS) in advanced colorectal cancer clinical trials.
    Garcia-Albeniz, X.
    Carrera, G.
    Feliu, J.
    Aparicio, J.
    Torres, F.
    Maurel, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Impact of clinical and biological markers on progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell cancer (NSCLC) treated by erlotinib: results of the ERMETIC cohort
    Cadranel, Jacques
    Lizard, Sarah
    Mauguen, Audrey
    Beau-Faller, Michele
    Friard, Sylvie
    Buisine, Marie-Pierre
    Pretet, Jean-luc
    Degeorges, Armelle
    Madelaine, Jeannick
    Chouaid, Christos
    Morin, Franck
    Pignon, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S502 - S503
  • [26] RELATIONSHIP OF PROGRESSION-FREE SURVIVAL, POST-PROGRESSION SURVIVAL AND RESPONSE WITH OVERALL SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER OF INDIVIDUAL-LEVEL
    Imai, Hisao
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    RESPIROLOGY, 2013, 18 : 85 - 85
  • [27] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Hoffknecht, Petra
    Mok, Tony
    Shaw, Alice I.
    Camidge, D. Ross
    Gadgeel, Shirish
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [28] Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials.
    Buyse, M
    Burzykowski, T
    Carroll, K
    Michiels, S
    Pignon, JP
    Piedbois, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [29] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
    Komaki, Ritsuko
    Allen, Pamela K.
    Wei, Xiong
    Blumenschein, George R.
    Tang, Ximing
    Lee, J. Jack
    Welsh, James W.
    Wistuba, Ignacio I.
    Liu, Diane D.
    Hong, Waun Ki
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (02): : 317 - 324
12345